Rezolute, Inc. (RZLT)
Rezolute is a Redwood City pharmaceutical company developing ersodetug to treat low blood sugar caused by hyperinsulinism. It last closed at $4.01 on Nov 17, up 12.15% on the day. RZLT reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 5 analysts is $10.80 (+169.0% from the last close), with a high of $15.00 and a low of $7.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From RZLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on RZLT in the past 90 days. The average target is $10.80, with a high of $15.00 and a low of $7.00, compared with the last close of $4.01.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | Wedbush | Target raised | Buy | $6 → $10 |
| Oct 6 | Lake Street | Target raised | Buy | $9 → $12 |
| Oct 6 | Citizens | Target raised | Buy | $11 → $15 |
| Sep 30 | Lake Street | Initiated | Buy | $9 |
| Sep 29 | Craig-Hallum | Upgrade | Buy | $7 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 2% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 51). The nearest support is the swing low (Sep 10) at $3.97, and the nearest resistance the 50 day average at $4.04.
| RSI (14) | 51.36 | Middle of its range | Neutral |
| MACD | -0.08 | Below its signal line | Bearish |
| Stochastic | 26.0 | Middle of its range | Neutral |
| ADX (14) | 12.4 | No clear trend | |
| Williams %R | -47.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -41.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +0.1% | Change over 10 sessions | Bullish |
| ATR (14) | $0.36 | Typical daily range, 9.1% of price |
| RSI (14) | 48.35 | Middle of its range | Neutral |
| MACD | -0.12 | Below its signal line | Bearish |
| Stochastic | 21.2 | Middle of its range | Neutral |
| ADX (14) | 18.5 | No clear trend | |
| Williams %R | -71.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -93.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −4.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.76 | Typical daily range, 19.0% of price |
What happened before
See how RZLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RZLT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in RZLT in the last 90 days.
RZLT Institutional Ownership
Full report →- ▼60 buying vs 76 selling
- ▼Held by funds -1.9 pts
- ▼Funds holding -10
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 136 | 146 | −6.8% |
| In funds' top 10 | 0 | 2 | −100.0% |
| Held by funds | 87.8% | 89.6% | −1.9 pts |
| New / increased | 18 / 42 | 39 / 60 | −39.4% |
| Reduced / sold out | 49 / 27 | 30 / 19 | +55.1% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RZLT is in one of them and how their past RZLT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RZLT in an article yet. Here's the latest on the wider market.
About Rezolute
Rezolute is a pharmaceutical company based in Redwood City, California, that is developing treatments for hypoglycemia, or dangerously low blood sugar, caused by hyperinsulinism. Its main candidate, ersodetug, is an intravenously given antibody that acts on the insulin receptor to help bring blood glucose back into a more normal range. The company is studying the drug in children with congenital hyperinsulinism and in patients with tumor-related hyperinsulinism. Its work is aimed at patients and families affected by these rare conditions, for whom current treatment options are limited.
- Headquarters
- Redwood City, CA

